Papers
2
Total Citations
26
H-Index
2
About
S. Bahrami is a radiation oncologist specializing in stereotactic body radiotherapy (SBRT) for breast cancer, with a focus on developing ultra-hypofractionated, single-fraction treatment protocols. Their major contribution lies in pioneering the use of single-fraction stereotactic partial breast irradiation (S-PBI) for early-stage breast cancer, a technique that delivers a highly conformal, ablative radiation dose in a single session rather than the conventional multi-week course. This approach aims to reduce treatment burden while maintaining tumor control and cosmetic outcomes. Bahrami’s most cited work, a 2021 multi-institutional Phase I dose-escalation trial (23 citations), established the safety and feasibility of this technique, reporting early toxicity and dose-limiting toxicity data that paved the way for larger Phase II studies. A subsequent 2021 follow-up (3 citations) provided longer-term outcomes, reinforcing the promise of S-PBI. These studies, conducted across multiple institutions, represent a significant step toward simplifying breast cancer radiotherapy, potentially reducing visits from weeks to a single day. Bahrami’s research is instrumental in shaping the future of breast cancer treatment, offering patients a more convenient and less disruptive option without compromising efficacy.
Research Focus
Key Achievements
Top Papers
- 1
- 2